Arthneeti
All Q1 FY27 results →
VS

Viyash Scientific

Q1 FY27Pharmaceuticals & Biotechnology

Viyash Scientific Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹278
Market cap₹12.1K Cr
P/E54.8
Updated25 Aug 2026
Read5 min read

What the Q1 FY27 call signalled

2 of 4 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
FundraiseFundraise planned

The short version

Expect steady double-digit revenue growth with 15%-17% growth in next 2 years (up to 2028) before acceleration. Company expects sustainable double-digit revenue growth, targeting around 15%-17% growth over the next 2 years. - Majority of new product revenue is expected from 2029 onwards due to product gestation and patent expiries. - The 2032 aspiration includes reaching revenues of $150-200 million in companion animal segment, supported by organic growth and inorganic acquisitions. - EBITDA margins targeted around 20%-22%, with continuous margin expansion expected. - Profit after tax doubled year-on-year in Q1 FY’27, indicating strong profitability momentum. - API and Animal Health segments to grow mid-teens to 20%+ over near term. - Acquisition synergy and market expansion in Europe to contribute to growth from 2029 onwards. - CAPEX planned in range of Rs.

From Viyash Scientific's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • Expect steady double-digit revenue growth with 15%-17% growth in next 2 years (up to 2028) before acceleration.
  • Significant growth anticipated post-2029, driven by patent expiries on Animal Health (2027-2033) and Human API products (post-2030).
  • Majority of new product revenues expected from 2029 onwards, considering 3-5 years gestation for product development and regulatory approvals.
  • Animal Health segment growing faster, currently about one-third of API revenue, with focus on formulations and expanding manufacturing capacity.
  • European acquisition (BioForLife) to contribute substantially after 2-3 years (post-2028) with estimated €150-200 million revenue by 2032.
  • Emerging markets (Turkey, Brazil, Mexico) showing strong volume growth (~25%), expected to sustain momentum.

2 more points from Viyash Scientific's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Viyash Scientific said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Capex guidance for FY’27 is around Rs. 250 crores to Rs. 300 crores.
  • Current capital allocation is balanced; majority business (90%) is mature and requires limited new investment.
  • New investments focus on R&D, manufacturing expansion, and strategic areas like high potent API and formulation capabilities.
  • Manufacturing plant for companion animal products being prepared with expected readiness by January-February following equipment orders placed and design finalization.
  • Company plans selective inorganic growth via acquisitions aligned with strategic direction (Animal Health, CDMO, complex molecules).
  • Interest cost restructuring underway to optimize financing costs.

2 more points from Viyash Scientific's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Viyash Scientific said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights include: - Post-acquisition of BioForLife (Italy), registrations and marketing are expected to take 18-24 months before significant revenue impact. - Product launches and R&D investments for companion animals are ramping up, with manufacturing readiness expected by January 2027. - A strong product pipeline in emerging markets (Turkey, Brazil, Mexico) and Europe supports growth. - API business faced some quarter-on-quarter timing delays due to raw material volatility but expects a strong quarter with many orders returning.

2 more points from Viyash Scientific's call on order book

Create a free account to keep reading this call

Viyash Scientific — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹920 Cr, net profit ₹66 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Viyash Scientific's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Viyash Scientific and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Viyash Scientific Q1 FY27 results?

Expect steady double-digit revenue growth with 15%-17% growth in next 2 years (up to 2028) before acceleration. Company expects sustainable double-digit revenue growth, targeting around 15%-17% growth over the next 2 years. - Majority of new product revenue is expected from 2029 onwards due to product gestation and patent expiries. - The 2032 aspiration includes reaching revenues of $150-200 million in companion animal segment, supported by organic growth and inorganic acquisitions. - EBITDA margins targeted around 20%-22%, with continuous margin expansion expected. - Profit after tax doubled year-on-year in Q1 FY’27, indicating strong profitability momentum. - API and Animal Health segments to grow mid-teens to 20%+ over near term. - Acquisition synergy and market expansion in Europe to contribute to growth from 2029 onwards. - CAPEX planned in range of Rs.

What is Viyash Scientific share price analysis?

Viyash Scientific currently shows a below-average growth signal. The stock trades at a P/E of 54.8 with a market cap of ₹12,139 Cr. Investors should review the full earnings analysis for detailed insights.

Is Viyash Scientific planning capital expenditure?

Capex guidance for FY’27 is around Rs.

Keep Viyash Scientific on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.